天梯

Pfizer cuts full-year outlook due to declining sales of Covid-19-related products_我的网站

一 |     并行科技（920493）：拟以不超过1.28亿元向叶城县昆仑电子商务有限公司、联创万通智算技术服务有限公司采购GPU算力服务器及配套IT设备 每经讯，并行科技8月25日发布公告称，北京并行科技股份有限公司或其合并报表范围内子公司拟向叶城县昆仑电子商务有限公司、联创万通（北京）智算技术服务有限公司采购GPU算力服务器及配套IT设备，采购合同金额预计不超过人民币约1.28亿元。    Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。    （记者谭玉涵）     免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。    每日经济新闻     。

Current article:http://olpy678.cuntoujuefourantapai.cfd/list_8l7uh/8ondu.html

Published on:12:21:59